Chronic Coronary Artery Disease (CAD)
Albany, NY (PRWEB) January 25, 2015
Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales(at)researchmoz(dot)us
A new research report that presents a pipeline review of chronic coronary artery disease (CAD), also known as Ischemic heart Disease, in the global market has been recently added to ResearchMoz.us’s extensive research report database. The report is titled “Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2014”.
To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=238822
The report presents a detailed study of the global chronic coronary artery disease (CAD) therapeutics landscape. Through a brief introduction about the numerous coronary artery diseases observed in humans, the report presents a competitive analysis of the market for drugs formulated for these conditions, with a prime focus on the chief pipeline drugs.
The report classifies the pipeline drugs according to therapeutic class, mechanism of action (MoA), monotherapy products, molecule type of the drug, and route of administration of the drug.
The report compiles details such as licensing data, collaborations, product description, and therapeutic assessment of these drugs. A detailed analysis of the drugs at different levels of development, along with latest updates and featured news about the drugs, is presented in the report.
To Browse a Full Report with TOC: http://www.researchmoz.us/chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h2-2014-report.html
The report delves into nearly 20 therapeutic fields and studies investigational drugs for nearly 3,000 indications in the global market for coronary artery diseases. The report presents profiles of drugs in classes such as ALD-201, Biglycan therapy, JVS-100, Cryocell, gene therapy for activating vascular endothelial growth factor, LA-419, Oligonucleotides, and ranolazine ER, among others.
The data is chiefly sourced from SEC filings, company and university websites, featured press releases, industry-specific third party sources, and investor presentations. All data related to the CAD pipeline drugs profiled in the report undergoes timely updates based on the most recent developments, through a detailed tracking of clinical trial registries, live news feeds, and browser-based alert boxes. A strict set of processes followed for updating the data ensures that the data is real-time and latest.
The report presents a detailed analysis of developments in CAD pipeline products at the competitor’s end by assessing the minor as well as major projects of key market players. The report also pays special attention to the CAD drug projects that are in later stages of completion or have been discontinued, to allow a clear understanding of factors that can drive projects out of the pipeline. Some of the key market players studied by the report include Gilead Sciences, Inc., Juventas Therapeutics, Inc., Human Stem Cells Institute, Nuo Therapeutics, Inc., and Lacer, S.A., among others.
By presenting a detailed overview of the various therapeutic areas on which key businesses are focusing, the report provides a way to develop effective business strategies for new market entrants. Also, by identifying the chief businesses with the most promising pipeline drugs, the report presents a way to devise effective M&A plans in the global market of CAD drugs.
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html